Tayside first in UK study recruitment and site opening
12th October 2017
In a boost to Scotland’s clinical research capabilities, NHS Tayside achieve top recruiter status and first site open in two important studies.
The international MARINER study aims to learn more about the possible prevention of blood clots after hospital discharge, and has seen NHS Tayside as its top recruiter. It will assess the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) and VTE-related death after hospital discharge of medically high-risk patients. Venous thromboembolism (VTE) is the name of a condition where normal blood flow in a blood vessel is restricted or blocked because of a blood clot. Depending on where the blood clot is, different terms are used. Deep vein thrombosis (DVT) is when the blood clot is in a deep vein. Pulmonary embolism (PE) is a blockage in a lung artery. The term VTE covers both types.
NHS Tayside is also the first UK site open to recruitment in a new cancer trial which aims to improve the treatment and outcomes for patients diagnosed with multiple myeloma using a combination of novel medicines. Multiple myeloma is the second most common haematological cancer in the European Union, causing around 21,000 deaths across EU countries in 2008. Approximately 20% of patients with myeloma have an extremely poor prognosis, with a survival rate of less than 3 years, and there has been no significant improvement of outcomes in the last decade for patients in this category.
These are important studies and demonstrate our commitment to working with stakeholders across NHS, academia and industry to maintain Scotland’s position as a world leader in clinical research.
Achievements, such as those by NHS Tayside exemplify our infrastructure, expertise and dedicated teams in action; and our work to ensure NHS Scotland provides the best environment to support clinical research.
Looking to find out more about how NRS support clinical research across Scotland?
- Watch our video with Nicola Sturgeon, First Minister of Scotland
- Read more about how we partner with industry
- Find out more about specific trials by downloading our case studies.